Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.
May 6, 2013
By:
Jill Wechsler
Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.
|
|
May 1, 2013
By:
Jill Wechsler
Legal battles and regulatory missteps undermine access to low-cost generics, at home and abroad.
|
Apr 1, 2013
By:
Jill Wechsler
There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices.
|
Mar 1, 2013
By:
Jill Wechsler
Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.
|
|
Feb 1, 2013
By:
Jill Wechsler
More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.
|
Jan 1, 2013
By:
Jill Wechsler
FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.
|
Dec 1, 2012
By:
Jill Wechsler
Tax and budget decisions will shape the healthcare market and drug research and regulation.
|
|
Nov 1, 2012
By:
Jill Wechsler
While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives, writes Jill Wechsler.
|
|
Oct 1, 2012
By:
Jill Wechsler
New user fee programs precipitate major changes at an agency under constant and intense scrutiny, writes Jill Wechsler.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
